Early hemoglobin response to epoetin alfa is associated with significantly better clinical outcomes in breast cancer patients

被引：0
|
作者：
Lefevbre, P
Rosberg, J
Duh, MS
McKenzie, RS
Fastenau, J
Piech, CT
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Ortho Biotech Clin Affairs LLC, Bridgewater, NJ USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2004年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S231 / S231
页数：1
相关论文
共 50 条
  • [21] A phase IV study of Epoetin alfa examining clinical outcomes in anaemic cancer patients receiving chemotherapy
    Glaspy, J
    Bukowski, R
    Steinberg, D
    Taylor, CW
    VadhanRaj, S
    Danna, RP
    Sarokhan, B
    Lonczak, L
    McNeill, M
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 233 - 233
  • [22] Epoetin alfa use in patients with ESRD: An analysis of recent US prescribing patterns and hemoglobin outcomes
    Collins, AJ
    Brenner, RM
    Ofman, JJ
    Chi, EM
    Stuccio-White, N
    Krishnan, M
    Solid, C
    Ofsthun, NJ
    Lazarus, JM
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 46 (03) : 481 - 488
  • [23] Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia
    Berger, Arlel
    Edelsberg, John
    Kallich, Joel
    Oster, Gerry
    CLINICAL THERAPEUTICS, 2008, 30 (01) : 206 - 218
  • [24] Effect of age on hemoglobin levels and quality of life following treatment with epoetin alfa in cancer patients
    Puglisi, Fabio
    Deroma, Laura
    Russo, Stefania
    Carteni, Giacomo
    Sporchia, Andrea
    Ucci, Giovanni
    De Signoribus, Giorgio
    Del Prete, Salvatore
    Vecchione, Aldo
    Pinotti, Graziella
    BeccagliaJ, Patrizia
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 69 (02) : 175 - 182
  • [25] Greater area under the hemoglobin change curve during epoetin alfa treatment is associated with improved patient outcomes
    Lefebvre, P
    Fastenau, JM
    Duh, MS
    Cremieux, P
    McKenzie, RS
    Piech, CT
    VALUE IN HEALTH, 2004, 7 (03) : 317 - 317
  • [26] Clinical benefits and risks associated with darbepoetin alfa and epoetin alfa treatment in patients with lung cancer and chemotherapy-induced anemia.
    Tiotiu, Angelica
    Clerc-Urmes, Isabelle
    Chabot, Francois
    Martinet, Yves
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Comparison of hemoglobin response in hospitalized hemodialysis patients receiving either epoetin alfa or darbepoetin alfa in an integrated health care system
    Lew, I
    Adamson, R
    PHARMACOTHERAPY, 2004, 24 (10): : 1446 - 1447
  • [28] Final report: epoetin alfa maintains hemoglobin levels and quality of life in breast cancer patients during conventional adjuvant chemotherapy.
    Hudis, C
    Williams, D
    Gralow, J
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S135 - S135
  • [29] Hematologic response to epoetin alfa correlates significantly with improved quality of life (QOL) in anemic cancer patients receiving myelotoxic chemotherapy (CT)
    Harousseau, Jean-Luc
    Lange, Winand
    Thomas, Hilary
    ANNALS OF ONCOLOGY, 2004, 15 : 220 - 220
  • [30] Use and outcomes of epoetin alfa and darbepoetin alfa for anemic cancer patients in outpatient community practice settings.
    Fahrbach, KR
    Frame, D
    Sercus, B
    Schenkel, B
    BLOOD, 2005, 106 (11) : 485B - 486B
12345